Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2019-12-16 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Positive results reaffirm plans to advance ATL1102 to P2b 6 pages 342.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 December 2019 from Antisense Therapeutics Limited. It details positive clinical trial results for ATL1102 in Duchenne Muscular Dystrophy (DMD), including safety, efficacy, and plans for advancing to a Phase IIb trial. The text includes detailed clinical data, expert commentary, trial design, and regulatory consultation updates. It is a comprehensive update on clinical trial progress and future plans rather than a formal financial report or regulatory filing. The document is lengthy (15,000 characters) and contains substantive information about the clinical trial results and company plans, typical of a Capital/Financing Update or clinical progress announcement. It is not an Annual Report, Earnings Release, or Management Discussion and Analysis. It is not a simple announcement of a report publication or a certification. Given the focus on clinical trial results and development plans, the best fitting category is Capital/Financing Update (CAP), as it relates to advancing a drug candidate which impacts company valuation and financing prospects.
2019-12-16 English
Reinstatement to Official Quotation 1 page 218.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to official quotation of Antisense Therapeutics Limited's securities following the release of an announcement about clinical trial results. It is a short notice about trading status and does not contain financial statements, detailed reports, or regulatory certifications. It is an official regulatory announcement related to market listing status, fitting best under Regulatory Filings (RNS).
2019-12-16 English
Suspension from Official Quotation 2 pages 447.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited regarding the immediate suspension of its securities from official quotation on the ASX, pending the release of a clinical trial results announcement. It references ASX Listing Rule 17.2 and is a formal request for suspension, not a financial report or detailed disclosure. The document is short (2260 characters) and serves as a regulatory announcement about trading suspension rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-12-15 English
Appendix 3B 13 pages 340.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose of the issue, and compliance with ASX rules. It also includes a calculation of placement capacity under ASX rules 7.1 and 7.1A, which relates to the company's ability to issue new shares without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a substantive announcement, not just a brief notice or report publication announcement.
2019-12-15 English
Change of Director's Interest Notice - RM 2 pages 223.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options acquired or disposed of, dates of changes, and nature of the transactions. There is no financial performance data, earnings information, or management discussion. The content is focused on insider share transactions by a director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3697 characters, which is typical for such notices and not a report publication announcement. Therefore, the correct classification is DIRS with high confidence.
2019-12-15 English
Trading Halt 2 pages 446.6KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited regarding a trading halt requested pending the release of an announcement about preliminary clinical trial results. It is a short notice about a trading halt and does not contain any financial data, report content, or detailed disclosures. It is an announcement related to market trading status rather than a financial report or regulatory filing with substantive content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-12-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.